The FDA's approvals database records a supplemental application dated 25 September 2026 on an adalimumab biosimilar, adalimumab-aqvh, under biologics licence application 761216. The entry gives the application number, the sponsor and the molecule, and nothing more.
A supplement to a biologics licence can cover a manufacturing site change, a presentation or device change such as a new autoinjector, a labelling revision, or an extension of indication — and for a biosimilar, manufacturing and presentation changes are the commonest. Nothing should be inferred about the product's indications or its interchangeability status from this record alone.
The reason to note it at all is supply. Biosimilar adalimumab products have proliferated, and a change at the manufacturing or presentation level is exactly the kind of event that later shows up in clinic as a patient arriving with a different-looking pen and asking whether it is the same drug. The useful preparation is to know which product your patients are actually dispensed, since in many systems that is decided by the pharmacy rather than the prescription.
In India adalimumab biosimilars are licensed separately by CDSCO from several domestic manufacturers, and this American record does not affect Indian supply or labelling. The device-familiarity point applies here too, and arguably more: a patient who has learned one injector and is switched to another needs the technique retaught, not assumed.
- Do not infer an indication change from a supplemental application record; supplements most often cover manufacturing or presentation
- Know which adalimumab product your patients are actually dispensed, since this is often decided at the pharmacy
- Reteach injection technique whenever a patient is switched between biosimilar devices rather than assuming transfer
- Check the current prescribing information rather than this entry if the question concerns indications
- Indian supply and labelling are set by CDSCO and are unaffected by this record
Why it matters
Biosimilar switches reach the patient through the pharmacy, and the first the clinic hears of one is usually a missed dose.
Don't overread it
This is an administrative database entry, not an approval of a new indication and not a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free